Combination of amlodipine plus angiotensin receptor blocker or diuretics in high-risk hypertensive patients: A 96-week efficacy and safety study

American Journal of Cardiovascular Drugs

Volumn 12, Issue 2, 2012, Pages 137-142

  Ma, Liyuan ^a   Wang, Wen ^a   Zhao, Yong ^b   Zhang, Yuqing ^a   Deng, Qing ^a   Liu, Mingbo ^a   Sun, Hui ^b   Wang, Jianchun ^b   Liu, Lisheng ^a,c  

^a FUWAI HOSPITAL   (China)

^b SHANDONG UNIVERSITY   (China)

^c Beijing Hypertension League Institute   (China)

Author keywords

amlodipine.; angiotensin II receptor blocker; antihypertensive therapy; diuretics; high risk

Indexed keywords

AMILORIDE PLUS HYDROCHLOROTHIAZIDE; AMLODIPINE; TELMISARTAN;

ADULT; AGED; ARTICLE; BLOOD PRESSURE REGULATION; CARDIOVASCULAR RISK; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; COUGHING; DIABETES MELLITUS; DIASTOLIC BLOOD PRESSURE; DIZZINESS; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ESSENTIAL HYPERTENSION; FEMALE; HEADACHE; HUMAN; HYPOKALEMIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PERIPHERAL EDEMA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION;

AGED; AMILORIDE; AMLODIPINE; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANTIHYPERTENSIVE AGENTS; BENZIMIDAZOLES; BENZOATES; BLOOD PRESSURE; CARDIOVASCULAR DISEASES; CHINA; DIURETICS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG COMBINATIONS; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYDROCHLOROTHIAZIDE; HYPERTENSION; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84863362902     PISSN: 11753277     EISSN: 1179187X     Source Type: Journal    
DOI: 10.2165/11598110-000000000-00000     Document Type: Article

References (34)

1. Wang L. 2002 National Nutrition and Health Survey: Report I [in Chinese], general report. People's Medical Publishing House: Beijing, 2005
2. Chobanian AV, Bakris GL, Black HR, et al. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. JAMA 2003; 289 (19): 2560-72 (Pubitemid 37430158)
3. Lopatriello S, Berto P. Long-term social costs of hypertension. Expert Rev Pharmacoeconomics Outcomes Res 2003; 3 (1): 33-40 (Pubitemid 36204451)
4. Zhang XH, Lu ZL, Liu L. Coronary heart disease in China. Heart 2008; 94 (9): 1126-31
5. Liu M, Wu B, Wang WZ, et al. Stroke in China: epidemiology, prevention, and management strategies. Lancet Neurol 2007; 6 (5): 456-64 (Pubitemid 46551849)
6. Liu L. Cardiovascular diseases in China. Biochem Cell Biol 2007; 85 (2): 157-63 (Pubitemid 46841682)
7. Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ 2009; 338: b1665
8. Wolf-Maier K, Cooper RS, Kramer H, et al. Hypertension treatment and control in five European countries, Canada, and the United States. Hypertension 2004; 43 (1): 10-7 (Pubitemid 38031904)
9. Wu Y, Huxley R, Li L, et al., China NNHS Steering Committee; ChinaNNHS Working Group. Prevalence, awareness, treatment, and control of hypertension in China: data from the China National Nutrition and Health Survey 2002. Circulation 2008; 118 (25): 2679-86
10. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatmet to Prevent Heart Attack Trial (ALLHAT). JAMA 2002; 288 (23): 2981-97
11. Dahlü f B, Sever PS, Poulter NR, et al., ASCOT Investigators. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 2005; 366 (9489): 895-906 (Pubitemid 41265663)
12. Jamerson K, Weber MA, Bakris GL, et al., ACCOMPLISH Trial Investigators. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med 2008; 359 (23): 2417-28
13. Mancia G, de Backer G, Dominiczak A, et al. 2007 Guidelines for the Management of Arterial Hypertension - The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007; 25 (6): 1105-87 (Pubitemid 46924065)
14. Gong L, Zhang W, Zhu Y, et al. Shanghai Trial of Nifedipine in the Elderly (STONE). J Hypertens 1996; 14 (10): 1237-45 (Pubitemid 26343504)
15. Wang JG, Staessen JA, Gong L, et al. Chinese trial on isolated systolic hypertension in the elderly. Systolic Hypertension in China (Syst-China) Collaborative Group. Arch Int Med 2000; 160 (2): 211-20 (Pubitemid 30054341)
16. Liu L, Zhang Y, Liu G, et al., FEVER Study Group. The Felodipine Event Reduction (FEVER) study: a randomized long-term placebo controlled trial in Chinese hypertensive patients. J Hypertens 2005; 23 (12): 2157-72 (Pubitemid 41666745)
17. Hashimoto J, Hirayama H, Hanasawa T, et al. Efficacy of combination antihypertensive therapy with low-dose indapamide: assessment by blood pressure self-monitoring at home. Clin Exp Hypertens 2005; 27 (4): 331-41 (Pubitemid 40686599)
18. Littlejohn 3rd TW, Majul CR, Olvera R, et al., Study Investigators. Results of treatment with telmisartan-amlodipine in hypertensive patients. J Clin Hypertens (Greenwich) 2009; 11 (4): 207-13
19. Littlejohn 3rd TW, Majul CR, Olvera R, et al., study investigators. Telmisartan plus amlodipine in patients with moderate or severe hypertension: results from a subgroup analysis of a randomized, placebo-controlled, parallelgroup, 4 4 factorial study. Postgrad Med 2009; 121 (2): 5-14
20. White WB, Littlejohn TW, Majul CR, et al. Effects of telmisartan and amlodipine in combination on ambulatory blood pressure in stages 1-2 hypertension. Blood Press Monit 2010; 15 (4): 205-12
21. Wang W, Ma L, Zhang Y, et al. The combination of amlodipine and angiotensin receptor blocker or diuretics in high-risk hypertensive patients: rationale, design and baseline characteristics. J Hum Hypertens 2011; 25 (4): 271-7
22. Mancia G, Laurent S, Agabiti-Rosei E, et al. Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. Blood Press 2009; 18 (6): 308-47
23. CalhounDA, CrikelairNA, Yen J, et al. Amlodipine/valsartan/ hydrochlorothiazide triple combination therapy in moderate/severe hypertension: secondary analyses evaluating efficacy and safety. Adv Ther 2009; 26 (11): 1012-23
24. Black HR, Elliott WJ, Grandits G, et al., CONVINCE Research Group. Principal results of the Controlled Onset Verapamil Investigation of Cardiovascular End Points (CONVINCE) trial. JAMA 2003; 289 (16): 2073-82 (Pubitemid 37430209)
25. Li H, Meng Q, Sun X, et al. Prevalence, awareness, treatment, and control of hypertension in rural China: results from Shandong Province. J Hypertens 2010; 28 (3): 432-8
26. Ong KL, Cheung BM, Man YB, et al. Prevalence, awareness, treatment, and control of hypertension among United States adults 1999-2004. Hypertension 2007; 49 (1): 69-75 (Pubitemid 46360343)
27. Cooper-DeHoff RM, Gong Y, Handberg EM, et al. Tight blood pressure control and cardiovascular outcomes among hypertensive patients with diabetes and coronary artery disease. JAMA 2010; 304 (1): 61-8
28. ACCORD Study Group, Cushman WC, EVans GW, Byington RP, et al. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med 2010; 362 (17): 1575-85
29. Smith TR, Glazer RD, Koren MJ, et al. Combination therapy with amlodipine/ valsartan in essential hypertension: a 52-week, randomised, open-label, extension study. Int J Clin Pract 2010; 64 (10): 1367-74
30. Philipp T, Smith TR, Glazer R, et al. Two multicenter, 8-week, randomized, double-blind, placebo-controlled, parallel-group studies evaluating the efficacy and tolerability of amlodipine and valsartan in combination and as monotherapy in adult patients with mild to moderate essential hypertension. Clin Ther 2007; 29 (4): 563-80 (Pubitemid 47028551)
31. Philipp T, Glazer RD, Zhao Y, et al. Long-term tolerability and efficacy of the combination of amlodipine/valsartan in hypertensive patients: a 54-week, open-label extension study. Curr Med Res Opin 2009; 25 (1): 187-93
32. Fogari R, Malamani GD, Zoppi A, et al. Effect of benazepril addition to amlodipine on ankle oedema and subcutaneous tissue pressure in hypertensive patients. J Hum Hypertens 2003; 17 (3): 207-12 (Pubitemid 36388805)
33. Fogari R, Zoppi A, Derosa G, et al. Effect of valsartan addition to amlodipine on ankle oedema and subcutaneous tissue pressure in hypertensive patients. J Hum Hypertens 2007; 21 (3): 220-4
34. Ogihara T, Saruta T, Rakugi H, et al., COLM study investigators. Rationale, study design and implementation of the COLM study: the combination of OLMesartan and calcium channel blocker or diuretic in high-risk elderly hypertensive patients. Hypertens Res 2009; 32 (2): 163-7